<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Epithalon: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-epithalon</link>
    <atom:link href="https://greypeptides.com/changes/epithalon.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Epithalon on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>New guide: Epitalon: the legal prescription route</title>
      <link>https://greypeptides.com/legal-access/epitalon/</link>
      <guid isPermaLink="false">greypeptides-changes-epithalon-guide-/legal-access/epitalon/</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found.</description>
    </item>
    <item>
      <title>News: Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30</title>
      <link>https://greypeptides.com/news/hhs-peptide-compounding-policy-fact-check/</link>
      <guid isPermaLink="false">greypeptides-changes-epithalon-news-hhs-peptide-compounding-policy-fact-check</guid>
      <pubDate>Wed, 04 Nov 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30</description>
    </item>
    <item>
      <title>Regulatory alert: US HHS (Office of the Secretary): HHS published a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon under set forms, routes and conditions, while FDA writes the 503A bulks list by rulemaking (91 FR 68526).</title>
      <link>https://greypeptides.com/regulatory/alerts/#hhs-peptide-enforcement-discretion</link>
      <guid isPermaLink="false">greypeptides-changes-epithalon-alert-hhs-peptide-enforcement-discretion</guid>
      <pubDate>Fri, 30 Oct 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Enforcement discretion, not a rule or an approval: the policy is non-binding, HHS may revisit it, and the conditions cover sourcing, a certificate of analysis, one peptide per product, labelling, an FDA-cleared syringe and adverse-event reporting. None of the six is on the 503A list or in Category 1; emideltide is not covered, and products sold outside a pharmacy are not covered.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA advisory committee: The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for FDA's 503A bulks list and voted against emideltide, as reported (BPC-157 8–6, 1 abstention; KPV 8–6, 1 abstention; TB-500 8–6, 1 abstention; MOTS-c 7–5, 2 abstentions; emideltide 6–7, 1 abstention; semax 8–5, 1 abstention; epitalon 7–4 or 7–5, 1 abstention).</title>
      <link>https://greypeptides.com/regulatory/alerts/#pcac-july-2026-votes</link>
      <guid isPermaLink="false">greypeptides-changes-epithalon-alert-pcac-july-2026-votes</guid>
      <pubDate>Fri, 24 Jul 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A committee recommendation is not a rule. As of November 4, 2026, FDA had posted no minutes or tallies, its 503A category list was still dated May 14, 2026, and none of the six was on the list or in Category 1. HHS's October 30 enforcement-discretion policy, logged separately, covers compounding of the six under its conditions; it does not add them to the list.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA gave notice in the Federal Register (91 FR 20465) of a July 23-24, 2026 committee meeting on seven peptides nominated for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.</title>
      <link>https://greypeptides.com/regulatory/alerts/#pcac-july-meeting-noticed</link>
      <guid isPermaLink="false">greypeptides-changes-epithalon-alert-pcac-july-meeting-noticed</guid>
      <pubDate>Thu, 16 Apr 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The first public review of these peptides for compounding, with a public docket (FDA-2025-N-6895) that took comments until July 22.</description>
    </item>
  </channel>
</rss>
